Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Sponsor
Marja-Riitta Taskinen
Study ID
NCT02948777
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 77 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Postprandial lipemia is highly prevalent in type 2 diabetes subjects even with normal fasting triglyceride values. Humans are mostly in a postprandial rather than in a fasting state and therefore non-fasting triglyceride values reflect more accurately the continuous exposure of arterial wall to the substantial cholesterol load from remnant particles. Evolocumab lowers blood LDL-cholesterol. This study evaluates the effect of evolocumab on postprandial lipid metabolism in type 2 diabetes. All participants in this study receive evolocumab treatment.

Key Dates

Start date
Oct 31, 2016
Status verified
Oct 2021
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Evolocumab
    Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks

Primary Outcome Measure

Mean ApoB Concentration Before and After Evolocumab [ Time Frame: Baseline and after 12 weeks ]

Related Studies